Nicholas J Viney1, Calvin Yeang2, Xiaohong Yang2, Shuting Xia1, Joseph L Witztum3, Sotirios Tsimikas4. 1. Ionis Pharmaceuticals, Carlsbad, CA, USA. 2. Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA. 3. Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA, USA. 4. Ionis Pharmaceuticals, Carlsbad, CA, USA; Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA. Electronic address: stsimikas@ucsd.edu.
Abstract
BACKGROUND: The laboratory measurement of "low-density lipoprotein cholesterol (LDL-C)" includes the cholesterol content of lipoprotein(a) (Lp(a)-C). OBJECTIVE: To estimate the "true" LDL-C in relation to changes in apolipoprotein B-100 (apoB-100) and assess changes in proprotein convertase subtilisin/kexin 9 (PCSK9) levels in patients with elevated Lp(a) treated with IONIS-APO(a)Rx. METHODS: A pooled placebo group (n = 29), and cohort A (n = 24, baseline Lp(a) 50-175 mg/dL) and cohort B (n = 8, baseline Lp(a) > 175 mg/dL) treated with IONIS-APO(a)Rx were studied. Lp(a) particle number, ultracentrifugation-measured "LDL-C", apoB-100, total PCSK9, and lipoprotein-associatedPCSK9 (PCSK9-Lp(a), PCSK9-apoB, PCSK9-apoAI) were measured. Lp(a)-cholesterol (Lp(a)-C) and LDL-C corrected for Lp(a)-C (LDL-Ccorr) were calculated. RESULTS:Baseline mean (standard deviation) "LDL-C" was 120 (42), 128 (45), and 112 (39) mg/dL in placebo, cohorts A and B, respectively, whereas LDL-Ccorr was 86 (48), 96 (43), and 57 (37) mg/dL (P < .001 compared with placebo), representing 28%, 25%, and 50% lower levels than "LDL-C". Following IONIS-APO(a)Rx treatment at day 85/99, Lp(a) particle number and Lp(a)-C decreased -66.8% and -71.6%, apoB-100 -10.3% and -17.5%, "LDL-C" -11.8% and -22.7%, (P < .001 for all vs placebo), whereas LDL-Ccorr increased +10.4% (P = .66) and +49.9% (P < .001) in cohorts A and B, respectively. Total PCSK9 did not change but PCSK9-Lp(a) decreased with IONIS-APO(a)Rx vs placebo (-39.0% vs +8.4%, P < .001). CONCLUSION: LDL-Ccorr is lower than laboratory "LDL-C" in patients with elevated Lp(a). Following apolipoprotein(a) inhibition and decline in Lp(a) and Lp(a)-C, the decline in apoB-100 is consistent with the notion that LDL devoid of apo(a) is cleared faster than Lp(a). These types of analyses may provide insights into the mechanisms of drugs affecting Lp(a) levels in clinical trials.
RCT Entities:
BACKGROUND: The laboratory measurement of "low-density lipoprotein cholesterol (LDL-C)" includes the cholesterol content of lipoprotein(a) (Lp(a)-C). OBJECTIVE: To estimate the "true" LDL-C in relation to changes in apolipoprotein B-100 (apoB-100) and assess changes in proprotein convertase subtilisin/kexin 9 (PCSK9) levels in patients with elevated Lp(a) treated with IONIS-APO(a)Rx. METHODS: A pooled placebo group (n = 29), and cohort A (n = 24, baseline Lp(a) 50-175 mg/dL) and cohort B (n = 8, baseline Lp(a) > 175 mg/dL) treated with IONIS-APO(a)Rx were studied. Lp(a) particle number, ultracentrifugation-measured "LDL-C", apoB-100, total PCSK9, and lipoprotein-associated PCSK9 (PCSK9-Lp(a), PCSK9-apoB, PCSK9-apoAI) were measured. Lp(a)-cholesterol (Lp(a)-C) and LDL-C corrected for Lp(a)-C (LDL-Ccorr) were calculated. RESULTS: Baseline mean (standard deviation) "LDL-C" was 120 (42), 128 (45), and 112 (39) mg/dL in placebo, cohorts A and B, respectively, whereas LDL-Ccorr was 86 (48), 96 (43), and 57 (37) mg/dL (P < .001 compared with placebo), representing 28%, 25%, and 50% lower levels than "LDL-C". Following IONIS-APO(a)Rx treatment at day 85/99, Lp(a) particle number and Lp(a)-C decreased -66.8% and -71.6%, apoB-100 -10.3% and -17.5%, "LDL-C" -11.8% and -22.7%, (P < .001 for all vs placebo), whereas LDL-Ccorr increased +10.4% (P = .66) and +49.9% (P < .001) in cohorts A and B, respectively. Total PCSK9 did not change but PCSK9-Lp(a) decreased with IONIS-APO(a)Rx vs placebo (-39.0% vs +8.4%, P < .001). CONCLUSION: LDL-Ccorr is lower than laboratory "LDL-C" in patients with elevated Lp(a). Following apolipoprotein(a) inhibition and decline in Lp(a) and Lp(a)-C, the decline in apoB-100 is consistent with the notion that LDL devoid of apo(a) is cleared faster than Lp(a). These types of analyses may provide insights into the mechanisms of drugs affecting Lp(a) levels in clinical trials.
Authors: Steven E Nissen; Kathy Wolski; Leslie Cho; Stephen J Nicholls; John Kastelein; Eran Leitersdorf; Ulf Landmesser; Michael Blaha; A Michael Lincoff; Ryuichi Morishita; Sotirios Tsimikas; Junhao Liu; Brian Manning; Plamen Kozlovski; Anastasia Lesogor; Tom Thuren; Taro Shibasaki; Florin Matei; Fábio Serra Silveira; Andreas Meunch; Aysha Bada; Vinod Vijan; Niels Eske Bruun; Borge G Nordestgaard Journal: Open Heart Date: 2022-10
Authors: Johan G Schnitzler; Renate M Hoogeveen; Lubna Ali; Koen H M Prange; Farahnaz Waissi; Michel van Weeghel; Julian C Bachmann; Miranda Versloot; Matthew J Borrelli; Calvin Yeang; Dominique P V De Kleijn; Riekelt H Houtkooper; Marlys L Koschinsky; Menno P J de Winther; Albert K Groen; Joseph L Witztum; Sotirios Tsimikas; Erik S G Stroes; Jeffrey Kroon Journal: Circ Res Date: 2020-03-12 Impact factor: 17.367
Authors: Rutger Verbeek; Renate M Hoogeveen; Anne Langsted; Lotte C A Stiekema; Simone L Verweij; G Kees Hovingh; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Børge G Nordestgaard; Erik S G Stroes Journal: Eur Heart J Date: 2018-07-14 Impact factor: 29.983
Authors: Sean A Burnap; Katherine Sattler; Raimund Pechlaner; Elisa Duregotti; Ruifang Lu; Konstantinos Theofilatos; Kaloyan Takov; Gerd Heusch; Sotirios Tsimikas; Carlos Fernández-Hernando; Sarah E Berry; Wendy L Hall; Marlene Notdurfter; Gregorio Rungger; Bernhard Paulweber; Johann Willeit; Stefan Kiechl; Bodo Levkau; Manuel Mayr Journal: Circ Res Date: 2021-10-04 Impact factor: 17.367